Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

On the number of stable solutions in the Kuramoto model

  • Arenas, Alex|||0000-0003-0937-0334
  • Garijo, Antoni|||0000-0002-1503-7514
  • Gómez, Sergio|||0000-0003-1820-0062
  • Villadelprat Yagüe, Jordi|||0000-0002-1168-9750
We consider a system of n coupled oscillators described by the Kuramoto model with the dynamics given by θ ˙ = ω + K f (θ). In this system, an equilibrium solution θ ∗ is considered stable when ω + K f (θ ∗) = 0, and the Jacobian matrix D f (θ ∗) has a simple eigenvalue of zero, indicating the presence of a direction in which the oscillators can adjust their phases. Additionally, the remaining eigenvalues of D f (θ ∗) are negative, indicating stability in orthogonal directions. A crucial constraint imposed on the equilibrium solution is that | Γ (θ ∗) | ≤ π, where | Γ (θ ∗) | represents the length of the shortest arc on the unit circle that contains the equilibrium solution θ ∗. We provide a proof that there exists a unique solution satisfying the aforementioned stability criteria. This analysis enhances our understanding of the stability and uniqueness of these solutions, offering valuable insights into the dynamics of coupled oscillators in this system.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immune digital twins for complex human pathologies: applications, limitations, and challenges

  • Niarakis, Anna
  • Montagud, Arnau
  • Valencia, Alfonso
Niarakis, Anna et al., Digital twins represent a key technology for precision health. Medical digital twins consist of computational models that represent the health state of individual patients over time, enabling optimal therapeutics and forecasting patient prognosis. Many health conditions involve the immune system, so it is crucial to include its key features when designing medical digital twins. The immune response is complex and varies across diseases and patients, and its modelling requires the collective expertise of the clinical, immunology, and computational modelling communities. This review outlines the initial progress on immune digital twins and the various initiatives to facilitate communication between interdisciplinary communities. We also outline the crucial aspects of an immune digital twin design and the prerequisites for its implementation in the clinic. We propose some initial use cases that could serve as "proof of concept" regarding the utility of immune digital technology, focusing on diseases with a very different immune response across spatial and temporal scales (minutes, days, months, years). Lastly, we discuss the use of digital twins in drug discovery and point out emerging challenges that the scientific community needs to collectively overcome to make immune digital twins a reality., This work is based on work during the three-week workshop on Building Immune Digital Twins, which was made possible by the support of the Institut Pascal, University of Paris-Saclay, France, via the program Investissements d’avenir, ANR-11-IDEX-0003-0. We would also like to thank Genopole for supporting the workshop. The authors also acknowledge the following support: AN was supported by a public-private partnership grant (CIFRE contract, no. 2020/0766) with SANOFI-AVENTIS R&D. R.L. acknowledges financial support from the Defense Advanced Research Projects Agency (grant HR00112220038), and the National Institutes of Health (grants R01 GM127909, R01 AI135128, and R01 HL169974). L.C.M., B.S., and L.G. acknowledge support from the European Commission (grants H2020-SC1-BHC-11-2020 963845 and Digital Europe EDITH-CSA 101083771). M.L.B. acknowledges support from the National Institutes of Health (grants R24 GM137787 and P41 EB023912). L.L.F. acknowledges financial support from the Defense Advanced Research Projects Agency (grant HR00112220038). L.H. acknowledged support from NIH/NCI Transition Career Development Award to Promote Diversity (K22-CA237857). L.S.V. acknowledges support from the National Institutes of Health (grants R01 AI135128, R01 HL169974, K25 AI175668). P.H. acknowledges support from the Prime Ministers’ Research Fellowship (PMRF). H.B. acknowledges the support of ZonMw (Grant No. 10430012010015) N.N. acknowledges support from the Knowledge Foundation (20200017) and The Swedish Fund for Research Without Animal Experiments. A.M., J.C.C., and A.V. acknowledge support from the European Commission (grants CREXDATA 101092749, PerMedCoE 951773, and EDITH-CSA 101083771). F.M. acknowledges support from the Italian Ministry of Health (grant “Ricerca Corrente” Linea 4 Project 5 and “5 per 1000–2021” Grant No. 5M-2021-23683787) and the European Commission with HORIZON programme (Grant No. 101046203—BY-COVID). J.A.G. acknowledges support from the National Institutes of Health (grants U24 EB028887) and the National Science Foundation (grants NSF 2303695, NSF 2120200, and NSF 1720625). G.A. and C.C. acknowledge support from the National Institutes of Health Award UO1EB025825 and the Defense Advanced Research Projects Agency through Cooperative Agreement D20AC00002 awarded by the U.S. Department of the Interior (DOI), Interior Business Center. K.R. was supported by the BMBF (Federal Ministry of Education and Research) in DAAD project 57616814 (SECAI, School of Embedded and Composite AI) as part of the program Konrad Zuse Schools of Excellence in Artificial Intelligence. Further, KR was supported by the imSAVAR and the CERTAINTY project. imSAVAR received funding from the Innovative Medicine Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL. The CERTAINTY project is funded by the European Union (Grant Agreement 101136379)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Experimentally calibrated multiscale model predicts schedule dependent drug combination effects

  • Hayoun-Mya, Othmane
  • Montagud, Arnau
  • Valencia, Alfonso
  • Ponce-de-Leon, Miguel
Therapeutic synergy emerges from interactions between molecular drug action, intracellular signaling, and tissue-level transport dynamics. We developed a multiscale model integrating these scales to predict schedule-dependent drug combination effect in the AGS cell line. Calibrated solely on single-drug growth curves, the model accurately predicted population-level outcomes of drug combinations without combination-specific training. This demonstrates the model’s capacity to suggest mechanistic multiscale insights into the logic of drug combinations within the AGS cell line, establishing a computational platform for the systematic in silico exploration of virtual multiscale experiments on drug diffusion and dosing schedules. Cross-scale analysis revealed that combination therapy efficacy flows across scales: population-level pharmacokinetics dictate the sequence of molecular target engagement within individual cells, determining collective cell-fate decisions. Our simulations predict that inhibiting the PI3K/AKT axis before MEK is more effective than the reverse order, disabling a pro-survival rebound and locking cells into an apoptotic state. Ultimately, by capturing phenomena that single-scale approaches cannot, this framework generates translationally relevant hypotheses, providing a versatile platform for optimizing drug scheduling, formulation, and combination strategies where matched molecular Boolean models and phenotypic data are available., This work was supported by the European Union’s Horizon Europe Research and Innovation programme projects HANAMI (grant agreement No. 101136269), by the Horizon 2020 projects CREXDATA (grant agreement No. 101092749) and PerMedCoE (grant agreement No. 951773) and by the ERA PerMed project Oncologics (ERAPERMED2020-036). O.H.M. was supported by a predoctoral “AGAUR-FI Joan Oró” fellowship from “Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generaliat de Catalunya i del Fons Europeu Social Plus” (2025 FI-1 01021)., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Assessing the impact of interregional mobility on COVID19 spread in Spain using transfer entropy

  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Pontes, Camila
  • Arenas, Alex
  • Valencia, Alfonso|||0000-0002-8937-6789
Human mobility played a key role in shaping the spatiotemporal dynamics of COVID19 transmission. This study employs Transfer Entropy (TE), an information-theoretic approach, to investigate the directional relationship between interregional mobility and COVID19 spread in Spain. Specifically, we use the mobility-associated risk time series, derived from phone-based origin–destination data and local infection prevalence, to estimate the flow of potentially infected individuals between regions. TE is then applied to measure the information flow from mobility-associated risk to regional case counts, enabling us to uncover spatio-temporal patterns of mobility-driven transmission. Using real-world data, we identified provinces that acted as outbreak drivers during the COVID19 pandemic in Spain and detected temporal shifts in the strength and direction of mobility’s influence. Our findings align with key epidemiological events, such as the 2020 summer outbreak in Lleida linked to seasonal workers, and highlight the effects of non-pharmaceutical interventions, including bar closures in Catalunya, on transmission dynamics. Finally, we validated our approach using simulations from a metapopulation SIR model with known transmission pathways, showing that TE can recover mobility-induced transmission structure while reducing indirect or spurious associations. Altogether, our work provides a novel approach to study the effect of interregional mobility on epidemic spread and to uncover spatio-temporal patterns of mobility-driven transmission, offering valuable insights to inform the timing and regional targeting of non-pharmaceutical interventions., This work has received funding from the Horizon 2020 project CREXDATA (ID: 101092749) and the MePreCiSa project of the UNICO I+D Cloud program, co-financed by the Ministry for Digital Transformation and of Civil Service and the EU-Next Generation EU as financing entities, within the framework of the PRTR and the MRR. CP was supported by the fellowship “Juan de la Cierva - Formación” from the Ministry of Education and Science of Spain (ID: FJC2021-046655-I). AA acknowledges support from the Spanish Ministerio de Ciencia e Innovación (PID2021-128005NB-C21), and the Joint Appointment Program at Pacific Northwest National Laboratory (PNNL). PNNL is a multi-program national laboratory operated for the U.S. Department of Energy (DOE) by Battelle Memorial Institute under Contract No. DE-AC05-76RL01830., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Contribución de congreso (ConferenceOutput)

Optimizing Resource Allocation for Tumor Simulations over HPC Infrastructures

  • Streviniotis, Errikos
  • Giatrakos, Nikos
  • Kotidis, Yannis
  • Ntiniakou, Thaleia
  • Ponce De Leon, Miguel|||0000-0002-7496-844X
We introduce RATS (Resource Allocator for Tumor Simulations), the first optimizer for the execution of tumor simulations over HPC infrastructures. The optimization framework of RATS incorporates 3 vital performance criteria (i) expected utility of a simulation in terms of effective drug combination on the simulated tumor, (ii) simulation execution time and (iii) number of cores required for achieving that execution time. RATS is to be used by life scientists at the Barcelona Supercomputing Center to not only remove the burden of blindly guessing the core hours we need to reserve from HPC admins to study various tumor treatment methodologies, but also to help in more rapidly distinguishing effective drug combinations, thus, potentially cutting time to market for new cancer therapies., E. Streviniotis, N. Giatrakos and Y. Kotidis were supported by the EU project EVENFLOW under Horizon Europe agreement No. 101070430. T. Ntiniakou and M. Ponce de Leon were supported by the EU project CREXDATA under Horizon Europe agreement No. 101092749., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Performance Assessment of an Electrostatic Filter-Diverter Stent Cerebrovascular Protection Device: Evaluation of a Range of Potential Electrostatic Fields Focusing on Small Particles

  • Eguzkitza, Beatriz|||0000-0002-3302-6667
  • Navia, José A
  • Houzeaux, Guillaume|||0000-0002-2592-1426
  • Butakoff, Constantine
  • Vázquez, Mariano|||0000-0002-2526-6708
Silent Brain Infarction (SBI) is increasingly recognized in patients with cardiac conditions, particularly Atrial Fibrillation (AF) in elderly patients and those undergoing Transcatheter Aortic Valve Implantation (TAVI). While these infarcts often go unnoticed due to a lack of acute symptoms, they are associated with a threefold increase in stroke risk and are considered a precursor to ischemic stroke. Moreover, accumulating evidence suggests that SBI may contribute to the development of dementia, depression, and cognitive decline, particularly in the elderly population. The burden of SBI is substantial, with studies showing that up to 11 million Americans may experience a silent stroke annually. In AF patients, silent brain infarcts are common and can lead to progressive brain damage, even in those receiving anticoagulation therapy. The use of cerebral embolic protection devices (CEPDs) during TAVI has been explored to mitigate the risk of stroke; however, their efficacy remains under debate. Despite advancements in TAVI technology, cerebrovascular events, including silent brain lesions, continue to pose significant challenges, underscoring the need for improved preventive strategies and therapeutic approaches. We propose a device consisting of a strut structure placed at the base of the treated artery to model the potential risk of cerebral embolisms caused by atrial fibrillation, thromboembolism, or dislodged debris of varying potential TAVI patients. The study has been carried out in two stages. Both are based on computational fluid dynamics (CFD) coupled with the Lagrangian particle tracking method. The first stage of the work evaluates a variety of strut thicknesses and inter-strut spacings, contrasting with the device-free baseline geometry. The analysis is carried out by imposing flow rate waveforms characteristic of healthy and AF patients. Boundary conditions are calibrated to reproduce physiological flow rates and pressures in a patient’s aortic arch. In the second stage, the optimal geometric design from the first stage was employed, with the addition of lateral struts to prevent the filtration of particles and electronegatively charged strut surfaces, studying the effect of electrical forces on the clots if they are considered charged. Flowrate boundary conditions were used to emulate both healthy and AF conditions. Results from numerical simulations coming from the first stage indicate that the device blocks particles of sizes larger than the inter-strut spacing. It was found that lateral strut space had the highest impact on efficacy. Based on the results of the second stage, deploying the electronegatively charged device in all three aortic arch arteries, the number of particles entering these arteries was reduced on average by 62.6 % and 51.2 %, for the healthy and diseased models respectively, matching or surpassing current oral anticoagulant efficacy. In conclusion, the device demonstrated a two-fold mechanism for filtering emboli: (1) while the smallest particles are deflected by electrostatic repulsion, avoiding micro embolisms, which could lead to cognitive impairment, the largest ones are mechanically filtered since they cannot fit in between the struts, effectively blocking the full range of particle sizes analyzed in this study. The device presented in this manuscript offers an anticoagulant-free method to prevent stroke and SBIs, imperative given the growing population of AF and elderly patients., This work was partially financed by the European Project “An ecosystem for digital twins in healthcare (EDITH)” under the call: DIGITAL-2021-DEPLOY-01-TWINS-HEALTH, Ref: 101083771. The research has been also supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 713673, by the project CompBioMed2 (H2020-EU.1.4.1.3. Grant No. 823712), by CREXDATA project (HORIZON-CL4-2022-DATA-01. Grant No. 101092749), and by the EIC Accelerator grant “ELVIS—ELEM Virtual Heart Populations for Supercomputers” Grant ID 190134524., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Performance assessment of an electrostatic filter-diverter stent cerebrovascular protection device. Is it possible not to use anticoagulants in atrial fibrilation elderly patients?

  • Eguzkitza, Beatriz|||0000-0002-3302-6667
  • Oks, David|||0000-0002-9659-0484
  • Navia, José A.
  • Houzeaux, Guillaume|||0000-0002-2592-1426
  • Butakoff, Constantine
  • Fisa, María
  • Campoy Millán, Ariadna
  • Vázquez, Mariano|||0000-0002-2526-6708
Stroke is the second leading cause of death worldwide. Nearly two-thirds of strokes are produced by cardioembolisms, and half of cardioembolic strokes are triggered by Atrial Fibrillation (AF), the most common type of arrhythmia. A more recent cause of cardioembolisms is Transcatheter Aortic Valve Replacements (TAVRs), which may onset post-procedural adverse events such as stroke and Silent Brain Infarcts (SBIs), for which no definitive treatment exists, and which will only get worse as TAVRs are implanted in younger and lower risk patients. It is well known that some specific characteristics of elderly patients may lower the safety and efficacy of anticoagulation therapy, making it a real urgency to find alternative therapies. We propose a device consisting of a strut structure placed at the base of the treated artery to model the potential risk of cerebral embolisms caused by dislodged debris of varying sizes. This work analyzes a design based on a patented medical device, intended to block cardioembolisms from entering the cerebrovascular system, with a particular focus on AF, and potentially TAVR patients. The study has been carried out in two stages. Both of them based on computational fluid dynamics (CFD) coupled with Lagrangian particle tracking method. The first stage of the work evaluates a variety of strut thicknesses and inter-strut spacings, contrasting with the device-free baseline geometry. The analysis is carried out by imposing flowrate waveforms characteristic of both healthy and AF patients. Boundary conditions are calibrated to reproduce physiological flowrates and pressures in a patient's aortic arch. In the second stage, the optimal geometric design from the first stage was employed, with the addition of lateral struts to prevent the filtration of particles and electronegatively charged strut surfaces, studying the effect of electrical forces on the clots if they are considered charged. Flowrate boundary conditions were used to emulate both healthy and AF conditions. Results from numerical simulations coming form the first stage indicate that the device blocks particles of sizes larger than the inter-strut spacing. It was found that lateral strut space had the highest impact on efficacy. Based on the results of the second stage, deploying the electronegatively charged device in all three aortic arch arteries, the number of particles entering these arteries was reduced on average by 62.6% and 51.2%, for the healthy and diseased models respectively, matching or surpassing current oral anticoagulant efficacy. In conclusion, the device demonstrated a two-fold mechanism for filtering emboli: while the smallest particles are deflected by electrostatic repulsion, avoiding microembolisms, which could lead to cognitive impairment, the largest ones are mechanically filtered since they cannot fit in between the struts, effectively blocking the full range of particle sizes analyzed in this study. The device presented in this manuscript offers an anticoagulant-free method to prevent stroke and SBIs, imperative given the growing population of AF and elderly patients., This research has been supported by “ELEM biotech - the virtual human factory” (www.elem.bio), an INPhINIT fellowship from “la Caixa” Foundation (fellowship ID: LCF/BQ/DI18/11660044), by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 713673., by the project CompBioMed2 (H2020-EU.1.4.1.3. Grant No. 823712), by CREXDATA project (HORIZON-CL4-2022-DATA-01. Grant No. 101092749) and by Torres Quevedo Program (PTQ2018-010290), Ministerio de Ciencia e Innovacion, Spain. ELEM Biotech was not involved in the study design, analysis, interpretation of data, the writing of this article or the decision to submit it for publication., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks

  • Ponce De Leon, Miguel|||0000-0002-7496-844X
  • Montagud, Arnau|||0000-0002-7696-1241
  • Noël, Vincent
  • Meert, Annika
  • Pradas, Gerard
  • Barillot, Emmanuel
  • Calzone, Laurence
  • Valencia, Alfonso|||0000-0002-8937-6789
In systems biology, mathematical models and simulations play a crucial role in understanding complex biological systems. Different modelling frameworks are employed depending on the nature and scales of the system under study. For instance, signalling and regulatory networks can be simulated using Boolean modelling, whereas multicellular systems can be studied using agent-based modelling. Herein, we present PhysiBoSS 2.0, a hybrid agent-based modelling framework that allows simulating signalling and regulatory networks within individual cell agents. PhysiBoSS 2.0 is a redesign and reimplementation of PhysiBoSS 1.0 and was conceived as an add-on that expands the PhysiCell functionalities by enabling the simulation of intracellular cell signalling using MaBoSS while keeping a decoupled, maintainable and model-agnostic design. PhysiBoSS 2.0 also expands the set of functionalities offered to the users, including custom models and cell specifications, mechanistic submodels of substrate internalisation and detailed control over simulation parameters. Together with PhysiBoSS 2.0, we introduce PCTK, a Python package developed for handling and processing simulation outputs, and generating summary plots and 3D renders. PhysiBoSS 2.0 allows studying the interplay between the microenvironment, the signalling pathways that control cellular processes and population dynamics, suitable for modelling cancer. We show different approaches for integrating Boolean networks into multi-scale simulations using strategies to study the drug effects and synergies in models of cancer cell lines and validate them using experimental data. PhysiBoSS 2.0 is open-source and publicly available on GitHub with several repositories of accompanying interoperable tools., The authors thank Paul Macklin and Randy Heiland for their support with the PhysiCell code and discussions. The authors acknowledge the technical expertise and assistance provided by the Spanish Supercomputing Network (Red Española de Supercomputación), as well as the computer resources used: the LaPalma Supercomputer (RES-BCV-2019-2-0008), located at the Instituto de Astrofísica de Canarias, and MareNostrum4 (RES-BCV-2019-2-0013, RES-BCV-2020-3-0016, RES-BCV-2021-2-0020), located at the Barcelona Supercomputing Center. This work has received funding from the Horizon 2020 projects: INFORE (ID: 825070), PerMedCoE (ID: 951773) and CREXDATA (ID: 101092749). This work has received funding from the Horizon 2020 projects INFORE (ID: 825070) and PerMedCoE (ID: 951773) and from the Horizon Europe project CREXDATA (ID: 101092749). This work was funded in part by the French government under the management of Agence Nationale de la Recherche as part of the “Investissements d’avenir” programme, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Contribución de congreso (ConferenceOutput)

Performance analysis of distributed GPU-accelerated task-based workflows

  • Nogueira Lobo de Carvalho, Marcos|||0000-0001-7015-9517
  • Queralt Calafat, Anna|||0000-0003-2782-2955
  • Romero Moral, Óscar|||0000-0001-6350-8328
  • Simitsis, Alkis
  • Tatu, Cristian
  • Badia Sala, Rosa Maria|||0000-0003-2941-5499
We present an empirical approach to identify the key factors affecting the execution performance of task-based workflows on a High Performance Computing (HPC) infrastructure composed of heterogeneous CPU-GPU clusters. Our results reveal that the execution performance in distributed GPU-accelerated task-based workflows highly depends on several interrelated factors regarding the task algorithm, dataset, resources, and system employed. In addition, our analysis identifies key correlations among these factors, presents novel observations, and offers guidelines toward designing an automated method to handle task-based workflows in modern, high-compute capacity, CPU-GPU engines., This work has been partially supported by DEDS (H2020-MSCAITN2020) with grant agreement No. 955895, the EU-HORIZON programme CREXDATA under GA.101092749, the EU-HORIZON programme FAIR-CORE4EOSC under GA.101057264, the EUHORIZON programme EXTREMEXP under GA.101093164, the Spanish Government projects PID2019-107255GB and PID2020117191RB-I00/AEI/10.13039/501100011033andMCIN/AEI/10.13039 /501100011033 (CEX2021-001148-S), and by the Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00412, MPiEDist)., Peer Reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Structured interactions drive abrupt transitions in the spatial organization of microbial communities

  • Mattei, Mattia
  • Soriano-Paños, David
  • Halappanavar, Mahantesh
  • Arenas, Alex
Bacteria possess diverse mechanisms to regulate their motility in response to environmental and physiological signals, enabling them to navigate complex habitats and adapt their behavior. Some of these mechanisms are species specific and enable cells to modulate their movement based on the ecological identity of neighboring species. Here, we introduce a model in which bacteria interact via local signals that either enhance or suppress the motility of neighboring cells depending on species type. Through large-scale simulations and a coarse-grained stochastic model, we demonstrate the emergence of a sharp transition driven by nucleation processes: increasing the density of motility-suppressing interactions drives the system from a fully mixed, motile phase to a state characterized by large, stationary bacterial clusters. Remarkably, in systems with a large number of interacting species, this transition can be triggered solely by altering the structure of the motility-regulation interaction matrix while maintaining species and interaction densities constant. In particular, we find that heterogeneous and modular interactions promote the transition more readily than homogeneous random ones. These findings add a dimension to the theory of motility-induced phase separation and contribute to the ongoing effort to understand microbial interactions, suggesting that structured, nonrandom ones may be key to reproducing commonly observed spatial patterns in microbial communities.
Recercat. Dipósit de la Recerca de Catalunya
Publication Contribución de congreso (ConferenceOutput)

Performance analysis of distributed GPU-accelerated task-based workflows

  • Nogueira Lobo de Carvalho, Marcos
  • Queralt Calafat, Anna
  • Romero Moral, Óscar
  • Simitsis, Alkis
  • Tatu, Cristian
  • Badia Sala, Rosa Maria
We present an empirical approach to identify the key factors affecting the execution performance of task-based workflows on a High Performance Computing (HPC) infrastructure composed of heterogeneous CPU-GPU clusters. Our results reveal that the execution performance in distributed GPU-accelerated task-based workflows highly depends on several interrelated factors regarding the task algorithm, dataset, resources, and system employed. In addition, our analysis identifies key correlations among these factors, presents novel observations, and offers guidelines toward designing an automated method to handle task-based workflows in modern, high-compute capacity, CPU-GPU engines., This work has been partially supported by DEDS (H2020-MSCAITN2020) with grant agreement No. 955895, the EU-HORIZON programme CREXDATA under GA.101092749, the EU-HORIZON programme FAIR-CORE4EOSC under GA.101057264, the EUHORIZON programme EXTREMEXP under GA.101093164, the Spanish Government projects PID2019-107255GB and PID2020117191RB-I00/AEI/10.13039/501100011033andMCIN/AEI/10.13039 /501100011033 (CEX2021-001148-S), and by the Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00412, MPiEDist)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Contribución de congreso (ConferenceOutput)

Optimizing Resource Allocation for Tumor Simulations over HPC Infrastructures

  • Streviniotis, Errikos
  • Giatrakos, Nikos
  • Kotidis, Yannis
  • Ntiniakou, Thaleia
  • Ponce De Leon, Miguel
We introduce RATS (Resource Allocator for Tumor Simulations), the first optimizer for the execution of tumor simulations over HPC infrastructures. The optimization framework of RATS incorporates 3 vital performance criteria (i) expected utility of a simulation in terms of effective drug combination on the simulated tumor, (ii) simulation execution time and (iii) number of cores required for achieving that execution time. RATS is to be used by life scientists at the Barcelona Supercomputing Center to not only remove the burden of blindly guessing the core hours we need to reserve from HPC admins to study various tumor treatment methodologies, but also to help in more rapidly distinguishing effective drug combinations, thus, potentially cutting time to market for new cancer therapies., E. Streviniotis, N. Giatrakos and Y. Kotidis were supported by the EU project EVENFLOW under Horizon Europe agreement No. 101070430. T. Ntiniakou and M. Ponce de Leon were supported by the EU project CREXDATA under Horizon Europe agreement No. 101092749., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PhysiBoSS 2.0: a sustainable integration of stochastic Boolean and agent-based modelling frameworks

  • Ponce De Leon, Miguel
  • Montagud, Arnau
  • Noël, Vincent
  • Meert, Annika
  • Pradas, Gerard
  • Barillot, Emmanuel
  • Calzone, Laurence
  • Valencia, Alfonso
In systems biology, mathematical models and simulations play a crucial role in understanding complex biological systems. Different modelling frameworks are employed depending on the nature and scales of the system under study. For instance, signalling and regulatory networks can be simulated using Boolean modelling, whereas multicellular systems can be studied using agent-based modelling. Herein, we present PhysiBoSS 2.0, a hybrid agent-based modelling framework that allows simulating signalling and regulatory networks within individual cell agents. PhysiBoSS 2.0 is a redesign and reimplementation of PhysiBoSS 1.0 and was conceived as an add-on that expands the PhysiCell functionalities by enabling the simulation of intracellular cell signalling using MaBoSS while keeping a decoupled, maintainable and model-agnostic design. PhysiBoSS 2.0 also expands the set of functionalities offered to the users, including custom models and cell specifications, mechanistic submodels of substrate internalisation and detailed control over simulation parameters. Together with PhysiBoSS 2.0, we introduce PCTK, a Python package developed for handling and processing simulation outputs, and generating summary plots and 3D renders. PhysiBoSS 2.0 allows studying the interplay between the microenvironment, the signalling pathways that control cellular processes and population dynamics, suitable for modelling cancer. We show different approaches for integrating Boolean networks into multi-scale simulations using strategies to study the drug effects and synergies in models of cancer cell lines and validate them using experimental data. PhysiBoSS 2.0 is open-source and publicly available on GitHub with several repositories of accompanying interoperable tools., The authors thank Paul Macklin and Randy Heiland for their support with the PhysiCell code and discussions. The authors acknowledge the technical expertise and assistance provided by the Spanish Supercomputing Network (Red Española de Supercomputación), as well as the computer resources used: the LaPalma Supercomputer (RES-BCV-2019-2-0008), located at the Instituto de Astrofísica de Canarias, and MareNostrum4 (RES-BCV-2019-2-0013, RES-BCV-2020-3-0016, RES-BCV-2021-2-0020), located at the Barcelona Supercomputing Center. This work has received funding from the Horizon 2020 projects: INFORE (ID: 825070), PerMedCoE (ID: 951773) and CREXDATA (ID: 101092749). This work has received funding from the Horizon 2020 projects INFORE (ID: 825070) and PerMedCoE (ID: 951773) and from the Horizon Europe project CREXDATA (ID: 101092749). This work was funded in part by the French government under the management of Agence Nationale de la Recherche as part of the “Investissements d’avenir” programme, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Performance Assessment of an Electrostatic Filter-Diverter Stent Cerebrovascular Protection Device: Evaluation of a Range of Potential Electrostatic Fields Focusing on Small Particles

  • Eguzkitza, Beatriz
  • Navia, José A
  • Houzeaux, Guillaume
  • Butakoff, Constantine
  • Vázquez, Mariano
Silent Brain Infarction (SBI) is increasingly recognized in patients with cardiac conditions, particularly Atrial Fibrillation (AF) in elderly patients and those undergoing Transcatheter Aortic Valve Implantation (TAVI). While these infarcts often go unnoticed due to a lack of acute symptoms, they are associated with a threefold increase in stroke risk and are considered a precursor to ischemic stroke. Moreover, accumulating evidence suggests that SBI may contribute to the development of dementia, depression, and cognitive decline, particularly in the elderly population. The burden of SBI is substantial, with studies showing that up to 11 million Americans may experience a silent stroke annually. In AF patients, silent brain infarcts are common and can lead to progressive brain damage, even in those receiving anticoagulation therapy. The use of cerebral embolic protection devices (CEPDs) during TAVI has been explored to mitigate the risk of stroke; however, their efficacy remains under debate. Despite advancements in TAVI technology, cerebrovascular events, including silent brain lesions, continue to pose significant challenges, underscoring the need for improved preventive strategies and therapeutic approaches. We propose a device consisting of a strut structure placed at the base of the treated artery to model the potential risk of cerebral embolisms caused by atrial fibrillation, thromboembolism, or dislodged debris of varying potential TAVI patients. The study has been carried out in two stages. Both are based on computational fluid dynamics (CFD) coupled with the Lagrangian particle tracking method. The first stage of the work evaluates a variety of strut thicknesses and inter-strut spacings, contrasting with the device-free baseline geometry. The analysis is carried out by imposing flow rate waveforms characteristic of healthy and AF patients. Boundary conditions are calibrated to reproduce physiological flow rates and pressures in a patient’s aortic arch. In the second stage, the optimal geometric design from the first stage was employed, with the addition of lateral struts to prevent the filtration of particles and electronegatively charged strut surfaces, studying the effect of electrical forces on the clots if they are considered charged. Flowrate boundary conditions were used to emulate both healthy and AF conditions. Results from numerical simulations coming from the first stage indicate that the device blocks particles of sizes larger than the inter-strut spacing. It was found that lateral strut space had the highest impact on efficacy. Based on the results of the second stage, deploying the electronegatively charged device in all three aortic arch arteries, the number of particles entering these arteries was reduced on average by 62.6 % and 51.2 %, for the healthy and diseased models respectively, matching or surpassing current oral anticoagulant efficacy. In conclusion, the device demonstrated a two-fold mechanism for filtering emboli: (1) while the smallest particles are deflected by electrostatic repulsion, avoiding micro embolisms, which could lead to cognitive impairment, the largest ones are mechanically filtered since they cannot fit in between the struts, effectively blocking the full range of particle sizes analyzed in this study. The device presented in this manuscript offers an anticoagulant-free method to prevent stroke and SBIs, imperative given the growing population of AF and elderly patients., This work was partially financed by the European Project “An ecosystem for digital twins in healthcare (EDITH)” under the call: DIGITAL-2021-DEPLOY-01-TWINS-HEALTH, Ref: 101083771. The research has been also supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 713673, by the project CompBioMed2 (H2020-EU.1.4.1.3. Grant No. 823712), by CREXDATA project (HORIZON-CL4-2022-DATA-01. Grant No. 101092749), and by the EIC Accelerator grant “ELVIS—ELEM Virtual Heart Populations for Supercomputers” Grant ID 190134524., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Performance assessment of an electrostatic filter-diverter stent cerebrovascular protection device. Is it possible not to use anticoagulants in atrial fibrilation elderly patients?

  • Eguzkitza, Beatriz
  • Oks, David
  • Navia, José A.
  • Houzeaux, Guillaume
  • Butakoff, Constantine
  • Fisa, María
  • Campoy Millán, Ariadna
  • Vázquez, Mariano
Stroke is the second leading cause of death worldwide. Nearly two-thirds of strokes are produced by cardioembolisms, and half of cardioembolic strokes are triggered by Atrial Fibrillation (AF), the most common type of arrhythmia. A more recent cause of cardioembolisms is Transcatheter Aortic Valve Replacements (TAVRs), which may onset post-procedural adverse events such as stroke and Silent Brain Infarcts (SBIs), for which no definitive treatment exists, and which will only get worse as TAVRs are implanted in younger and lower risk patients. It is well known that some specific characteristics of elderly patients may lower the safety and efficacy of anticoagulation therapy, making it a real urgency to find alternative therapies. We propose a device consisting of a strut structure placed at the base of the treated artery to model the potential risk of cerebral embolisms caused by dislodged debris of varying sizes. This work analyzes a design based on a patented medical device, intended to block cardioembolisms from entering the cerebrovascular system, with a particular focus on AF, and potentially TAVR patients. The study has been carried out in two stages. Both of them based on computational fluid dynamics (CFD) coupled with Lagrangian particle tracking method. The first stage of the work evaluates a variety of strut thicknesses and inter-strut spacings, contrasting with the device-free baseline geometry. The analysis is carried out by imposing flowrate waveforms characteristic of both healthy and AF patients. Boundary conditions are calibrated to reproduce physiological flowrates and pressures in a patient's aortic arch. In the second stage, the optimal geometric design from the first stage was employed, with the addition of lateral struts to prevent the filtration of particles and electronegatively charged strut surfaces, studying the effect of electrical forces on the clots if they are considered charged. Flowrate boundary conditions were used to emulate both healthy and AF conditions. Results from numerical simulations coming form the first stage indicate that the device blocks particles of sizes larger than the inter-strut spacing. It was found that lateral strut space had the highest impact on efficacy. Based on the results of the second stage, deploying the electronegatively charged device in all three aortic arch arteries, the number of particles entering these arteries was reduced on average by 62.6% and 51.2%, for the healthy and diseased models respectively, matching or surpassing current oral anticoagulant efficacy. In conclusion, the device demonstrated a two-fold mechanism for filtering emboli: while the smallest particles are deflected by electrostatic repulsion, avoiding microembolisms, which could lead to cognitive impairment, the largest ones are mechanically filtered since they cannot fit in between the struts, effectively blocking the full range of particle sizes analyzed in this study. The device presented in this manuscript offers an anticoagulant-free method to prevent stroke and SBIs, imperative given the growing population of AF and elderly patients., This research has been supported by “ELEM biotech - the virtual human factory” (www.elem.bio), an INPhINIT fellowship from “la Caixa” Foundation (fellowship ID: LCF/BQ/DI18/11660044), by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 713673., by the project CompBioMed2 (H2020-EU.1.4.1.3. Grant No. 823712), by CREXDATA project (HORIZON-CL4-2022-DATA-01. Grant No. 101092749) and by Torres Quevedo Program (PTQ2018-010290), Ministerio de Ciencia e Innovacion, Spain. ELEM Biotech was not involved in the study design, analysis, interpretation of data, the writing of this article or the decision to submit it for publication., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Assessing the impact of interregional mobility on COVID19 spread in Spain using transfer entropy

  • Ponce De Leon, Miguel
  • Pontes, Camila
  • Arenas, Alex
  • Valencia, Alfonso
Human mobility played a key role in shaping the spatiotemporal dynamics of COVID19 transmission. This study employs Transfer Entropy (TE), an information-theoretic approach, to investigate the directional relationship between interregional mobility and COVID19 spread in Spain. Specifically, we use the mobility-associated risk time series, derived from phone-based origin–destination data and local infection prevalence, to estimate the flow of potentially infected individuals between regions. TE is then applied to measure the information flow from mobility-associated risk to regional case counts, enabling us to uncover spatio-temporal patterns of mobility-driven transmission. Using real-world data, we identified provinces that acted as outbreak drivers during the COVID19 pandemic in Spain and detected temporal shifts in the strength and direction of mobility’s influence. Our findings align with key epidemiological events, such as the 2020 summer outbreak in Lleida linked to seasonal workers, and highlight the effects of non-pharmaceutical interventions, including bar closures in Catalunya, on transmission dynamics. Finally, we validated our approach using simulations from a metapopulation SIR model with known transmission pathways, showing that TE can recover mobility-induced transmission structure while reducing indirect or spurious associations. Altogether, our work provides a novel approach to study the effect of interregional mobility on epidemic spread and to uncover spatio-temporal patterns of mobility-driven transmission, offering valuable insights to inform the timing and regional targeting of non-pharmaceutical interventions., This work has received funding from the Horizon 2020 project CREXDATA (ID: 101092749) and the MePreCiSa project of the UNICO I+D Cloud program, co-financed by the Ministry for Digital Transformation and of Civil Service and the EU-Next Generation EU as financing entities, within the framework of the PRTR and the MRR. CP was supported by the fellowship “Juan de la Cierva - Formación” from the Ministry of Education and Science of Spain (ID: FJC2021-046655-I). AA acknowledges support from the Spanish Ministerio de Ciencia e Innovación (PID2021-128005NB-C21), and the Joint Appointment Program at Pacific Northwest National Laboratory (PNNL). PNNL is a multi-program national laboratory operated for the U.S. Department of Energy (DOE) by Battelle Memorial Institute under Contract No. DE-AC05-76RL01830., Peer Reviewed, Postprint (published version)